Capricor Therapeutics appoints Michael Kelliher to Board of Directors

CAPRICOR THERAPEUTICS, INC.

Michael Kelliher appointed to Board effective September 1, 2023; Board size increased from 8 to 9.
Kelliher is Group VP of M&A and Business Development at Horizon Therapeutics; 20+ years biotech/pharma experience.
Receives initial nonstatutory stock option for 115,000 shares vesting over 3 years (25% at 1 year, then monthly).
Will enter standard indemnification agreement; no committees assigned initially.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Kelliher

Director

CAPR · CAPRICOR THERAPEUTICS, INC.

Effective: 2023-09-01
Filed: September 6, 2023, 7:59 PM ET

On September 1, 2023, the Board of Directors (the “Board”) of Capricor Therapeutics, Inc. (the “Company”), pursuant to the authority given to it under the Certificate of Incorporation and Bylaws of the Company, approved an increase of the size of the Board from eight to nine directors, and thereafter elected Michael Kelliher as a member of the Board to fill the newly created vacancy, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Kelliher was elected as Director at CAPRICOR THERAPEUTICS, INC..

Action: elected
Role: Director

Exact text from the filing

On September 1, 2023, the Board of Directors (the “Board”) of Capricor Therapeutics, Inc. (the “Company”), pursuant to the authority given to it under the Certificate of Incorporation and Bylaws of the Company, approved an increase of the size of the Board from eight to nine directors, and thereafter elected Michael Kelliher as a member of the Board to fill the newly created vacancy, effective immediately.

View on SEC.gov

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-015482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.